Bone health is a lifelong journey, and women must prioritize it to avoid fractures and mobility issues later in life. Simple ...

In one of the first studies of its kind, a team of researchers from Keck School of Medicine of USC has found that proteins ...

The global osteoporosis drugs market size was valued at USD 14.90 billion in 2024 and is projected to reach USD 15.39 billion ...

Should you take a calcium supplement? And if so, how much? Here's what to know about calcium's benefits and some warnings.

A new study published in the journal of BMC Gasteroenterology found that patients with the liver cirrhosis had higher risk of ...

Implementing opportunistic computed tomography (CT) bone density screening could increase the osteoporosis screening rate, yielding a reduction in medical costs.

A new study from the Keck School of Medicine at USC has found that proteins linked to inflammation may play a role in bone ...

The "Osteoporosis_Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an overview of Osteoporosis Clinical ...

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD in postmenopausal women with T2D.

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).